Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Glenmark Launches CD38xCD3 Phase 1 Trial for Bispecific Antibody GBR 1342

americanpharmaceuticalreviewNovember 10, 2018

Tag: Glenmark , Solid Tumors , GBR 1342

PharmaSources Customer Service